Impact of immune checkpoint inhibitors on COVID-19 severity in patients with cancer
R Tan, C Yun, A Seetasith, D Sheinson, R Walls… - The …, 2022 - academic.oup.com
Background Amid continued uncertainty about the management of cancer patients during
the pandemic, this study sought to obtain real-world data on the use of immune checkpoint …
the pandemic, this study sought to obtain real-world data on the use of immune checkpoint …
COVID-19 in cancer patients
SL Seneviratne, W Wijerathne… - Transactions of the …, 2022 - academic.oup.com
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2, has currently affected> 220 million individuals worldwide. The …
syndrome coronavirus 2, has currently affected> 220 million individuals worldwide. The …
Virtual tumor board increases provider attendance and case presentations
CH Davis, J Ho, R Stephenson, DA August… - JCO Oncology …, 2022 - ascopubs.org
PURPOSE: Many cancer centers engage in multidisciplinary tumor board meetings to
determine the optimal approach to complex cancer care. With the onset of the COVID-19 …
determine the optimal approach to complex cancer care. With the onset of the COVID-19 …
Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19
SM Rubinstein, D Bhutani, RC Lynch, CY Hsu… - Blood cancer …, 2022 - AACR
Patients with B-lymphoid malignancies have been consistently identified as a population at
high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in …
high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in …
Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients
Y Leyfman, N Emmanuel, GP Menon, M Joshi… - Journal of Hematology & …, 2023 - Springer
Cancer patients, due to their immunocompromised status, are at an increased risk for severe
SARS-CoV-2 infection. Since severe SARS-CoV-2 infection causes multiple organ damage …
SARS-CoV-2 infection. Since severe SARS-CoV-2 infection causes multiple organ damage …
Reviewing treatment options for advanced renal cell carcinoma: Is there still a place for tyrosine kinase inhibitor (TKI) monotherapy?
M Fontes-Sousa, H Magalhaes, A Oliveira… - Advances in …, 2022 - Springer
Renal cell carcinoma (RCC) comprises a highly heterogeneous group of kidney tumours
built upon distinct genetic-and epigenetic-driven mechanisms and molecular pathways …
built upon distinct genetic-and epigenetic-driven mechanisms and molecular pathways …
Quality of Life in Patients with Pancreatic Cancer before and during the COVID-19 Pandemic
A Alexander, S Fung, M Eichler… - International journal of …, 2022 - mdpi.com
Background: Coronavirus disease 19 (COVID-19) substantially affects cancer patients due
to adverse outcomes and disruptions in cancer care. Recent studies have indicated the …
to adverse outcomes and disruptions in cancer care. Recent studies have indicated the …
Delineating the SARS-CoV-2 induced interplay between the host immune system and the DNA damage response network
COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus and
characterized by an extremely variable disease course, ranging from asymptomatic cases to …
characterized by an extremely variable disease course, ranging from asymptomatic cases to …
[HTML][HTML] The impact of the COVID-19 pandemic on cancer incidence and treatment by cancer stage in Bavaria, Germany
S Voigtländer, A Hakimhashemi… - Deutsches Ärzteblatt …, 2021 - ncbi.nlm.nih.gov
Methods Data were retrieved from the population-based Bavarian Cancer Registry (to 26
March 2021). We included all incident cancer cases and cancer treatments reported by …
March 2021). We included all incident cancer cases and cancer treatments reported by …
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma
A Aleman, M Van Kesteren, AK Zajdman… - …, 2023 - thelancet.com
Background The real-world impact of bivalent vaccines for wild type (WA. 1) and Omicron
variant (BA. 5) is largely unknown in immunocompromised patients with Multiple Myeloma …
variant (BA. 5) is largely unknown in immunocompromised patients with Multiple Myeloma …